In the latest market close, AngioDynamics (ANGO) reached $6.09, with a -0.98% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.57% for the day. Elsewhere, the Dow saw a downswing of 0.14%, while the tech-heavy Nasdaq appreciated by 1.25%.The medical device maker's shares have seen an increase of 1.49% over the last month, not keeping up with the Medical sector's gain of 2.05% and the S&P 500's gain of 5.07%.The upcoming earnings release of AngioDynamic ...

AngioDynamics, Inc. (ANGO) recently announced the US Food and Drug Administration (FDA) clearance for the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disease (PAD).With this 225-cm catheter length, access points in Atherectomy procedures can be expanded, which can help reduce access site complications and accelerate patient recovery.Price PerformanceFor the past six months, ANGO’s shares have plunged 31.0% compared w ...

AngioDynamics, Inc. (ANGO) reported an adjusted loss per share of 5 cents for second-quarter fiscal 2024, against the year-ago earnings per share (EPS) of a penny. However, the adjusted loss per share was narrower than the Zacks Consensus Estimate of a loss of 9 cents per share.Excluding Dialysis and BioSentry, on a pro-forma basis, adjusted loss per share in second-quarter fiscal 2024 was also 5 cents, narrower than the adjusted loss per share of 9 cents in the year-ago period.GAAP loss per share was 72 ce ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioD ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q2 2024 Earnings Conference Call January 5, 2024 8:00 AM ET Company Participants Jim Clemmer - President and CEO Steve Trowbridge - EVP and CFO Conference Call Participants Yi Chen - H.C. Wainwright John Young - Canaccord Genuity Jayson Bedford - Raymond James Steven Lichtman - Oppenheimer Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2024 Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and- ...

AngioDynamics Second Quarter 2024 Earnings Presentation Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of ...

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | |--------------------------------------------------------------------------------------------| | For the transition period from to Commission file number 0-50761 | | AngioDyn ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2024 Earnings Conference Call October 4, 2023 8:00 AM ET Company Participants Jim Clemmer - President & CEO Steve Trowbridge - EVP & CFO Conference Call Participants Jayson Bedford - Raymond James Steve Lichtman - Oppenheimer John Young - Canaccord Genuity Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2024 First Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-----------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------- ...

AngioDynamics, Inc. (NASDAQ:ANGO) Q4 2023 Earnings Conference Call July 12, 2023 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jason Bedford - Raymond James Bill Plovanic - Canaccord Genuity Matthew Mishan - KeyBanc Capital Markets Operator Good morning, and welcome to the AngioDynamics Fourth Quarter and Fiscal Year 2023 Earnings Call. At this time, all participants are ...